BRPI0506550A - uso do metronidazol para a preparação de uma composição farmacêutica - Google Patents

uso do metronidazol para a preparação de uma composição farmacêutica

Info

Publication number
BRPI0506550A
BRPI0506550A BRPI0506550-0A BRPI0506550A BRPI0506550A BR PI0506550 A BRPI0506550 A BR PI0506550A BR PI0506550 A BRPI0506550 A BR PI0506550A BR PI0506550 A BRPI0506550 A BR PI0506550A
Authority
BR
Brazil
Prior art keywords
metronidazole
preparation
pharmaceutical composition
receptor
pac
Prior art date
Application number
BRPI0506550-0A
Other languages
English (en)
Inventor
Fabrizio Dolfi
Irina Safonova
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of BRPI0506550A publication Critical patent/BRPI0506550A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"USO DO METRONIDAZOL PARA A PREPARAçãO DE UMA COMPOSIçãO FARMACêUTICA". A presente invenção trata do uso do metronidazol para a preparação de uma composição farmacêutica destinada a tratar as patologias que envolvem pelo menos um receptor escolhido no grupo que compreende o receptor IL-8RB e o receptor PAC-1.
BRPI0506550-0A 2004-02-20 2005-02-17 uso do metronidazol para a preparação de uma composição farmacêutica BRPI0506550A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0401721A FR2866569B1 (fr) 2004-02-20 2004-02-20 Utilisation du metronidazole pour la preparation d'une composition pharmaceutique destinee a traiter des pathologies liees au recepteur de type b de l'interleukine 8 et/ou au recepteur de type 1 de pacap
PCT/FR2005/000370 WO2005089750A2 (fr) 2004-02-20 2005-02-17 Utilisation du metronidazole pour le traitement des pathologies liees au recepteur de type b de l’interleukine 8 et/ou recepteur de type 1 de pacap

Publications (1)

Publication Number Publication Date
BRPI0506550A true BRPI0506550A (pt) 2007-02-27

Family

ID=34833946

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506550-0A BRPI0506550A (pt) 2004-02-20 2005-02-17 uso do metronidazol para a preparação de uma composição farmacêutica

Country Status (11)

Country Link
US (1) US20080221189A1 (pt)
EP (1) EP1718296A2 (pt)
JP (1) JP2007523133A (pt)
KR (1) KR20060124707A (pt)
CN (1) CN1921852A (pt)
AU (1) AU2005224123A1 (pt)
BR (1) BRPI0506550A (pt)
CA (1) CA2553932A1 (pt)
FR (1) FR2866569B1 (pt)
RU (1) RU2006133534A (pt)
WO (1) WO2005089750A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961695B1 (fr) * 2010-06-29 2012-07-06 Galderma Res & Dev Utilisation de composes dans le traitement ou la prevention de troubles cutanes
US20130102572A1 (en) * 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837378A (en) * 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
FR2722098B1 (fr) * 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
CA2161737C (en) * 1995-10-30 1998-10-20 Richard J. Mackay Metronidazole gel
GB9626513D0 (en) * 1996-12-20 1997-02-05 Bioglan Ireland R & D Ltd A pharmaceutical composition
US6365616B1 (en) * 1998-08-31 2002-04-02 Sentron Medical, Inc. Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases
KR100671879B1 (ko) * 1999-07-16 2007-01-19 가부시키가이샤 쇼에이 니트로이미다졸 함유 피부 질환용 외용제
CA2446356C (en) * 2001-05-09 2012-07-10 The Regents Of The University Of Michigan Use of compositions for treating rosacea
ES2279391T3 (es) * 2003-06-18 2007-08-16 Galderma S.A. Composicion farmaceutica topica de tintura verde a base de metronidazol.

Also Published As

Publication number Publication date
CA2553932A1 (fr) 2005-09-29
US20080221189A1 (en) 2008-09-11
FR2866569A1 (fr) 2005-08-26
WO2005089750A3 (fr) 2006-05-04
RU2006133534A (ru) 2008-03-27
JP2007523133A (ja) 2007-08-16
KR20060124707A (ko) 2006-12-05
CN1921852A (zh) 2007-02-28
AU2005224123A1 (en) 2005-09-29
FR2866569B1 (fr) 2007-08-24
EP1718296A2 (fr) 2006-11-08
WO2005089750A2 (fr) 2005-09-29

Similar Documents

Publication Publication Date Title
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
CL2007002578A1 (es) Compuestos derivados de n-(1-ftalazin-1-il-piperidin-4-il)-amidas; composicion farmaceutica; y uso para el tratamiento y prevencion de trastornos de la fertilidad, osteoporosis y cancer.
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
BRPI0910182A2 (pt) composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
ECSP088800A (es) Formulaciones de inhibidores de DPP IV
TW200716584A (en) Dihydrobenzofuran derivatives and uses thereof
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
BRPI0712631B8 (pt) compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
BRPI0717219A2 (pt) "composição imunogênica, método para tratar ou prevenir doença, e, uso de uma composição imunogênica."
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
CL2007001388A1 (es) Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer.
BRPI0408353A (pt) composto, composição farmacêutica, métodos para o tratamento de neoplasias suscetìveis e para o tratamento de infecções virais, e, uso de um composto
BRPI0413353A (pt) composição farmacêutica contendo droga solúvel em água
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
BRPI0508051A (pt) derivados de heteroarilaminopirazol utilizáveis para o tratamento de diabetes
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]